Valeo Financial Advisors LLC Increases Stake in DexCom, Inc. $DXCM

Valeo Financial Advisors LLC raised its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 23.7% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 10,250 shares of the medical device company’s stock after buying an additional 1,962 shares during the period. Valeo Financial Advisors LLC’s holdings in DexCom were worth $895,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. SWS Partners purchased a new stake in DexCom during the second quarter valued at approximately $1,661,000. Baader Bank Aktiengesellschaft purchased a new stake in DexCom during the second quarter valued at approximately $393,000. Assenagon Asset Management S.A. increased its holdings in DexCom by 85.7% during the second quarter. Assenagon Asset Management S.A. now owns 1,208,255 shares of the medical device company’s stock valued at $105,469,000 after buying an additional 557,576 shares during the last quarter. Mn Services Vermogensbeheer B.V. increased its holdings in DexCom by 4.9% during the second quarter. Mn Services Vermogensbeheer B.V. now owns 146,600 shares of the medical device company’s stock valued at $12,797,000 after buying an additional 6,800 shares during the last quarter. Finally, Golden State Wealth Management LLC increased its holdings in DexCom by 211.2% during the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company’s stock valued at $27,000 after buying an additional 264 shares during the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at DexCom

In related news, Director Kyle Malady sold 667 shares of the firm’s stock in a transaction on Friday, September 5th. The shares were sold at an average price of $80.86, for a total transaction of $53,933.62. Following the completion of the transaction, the director directly owned 22,667 shares of the company’s stock, valued at approximately $1,832,853.62. This trade represents a 2.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Mark G. Foletta sold 2,750 shares of the firm’s stock in a transaction on Friday, August 15th. The shares were sold at an average price of $81.06, for a total transaction of $222,915.00. Following the transaction, the director directly owned 51,121 shares of the company’s stock, valued at $4,143,868.26. The trade was a 5.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 6,849 shares of company stock valued at $564,733. Insiders own 0.32% of the company’s stock.

DexCom Stock Performance

DXCM opened at $66.03 on Wednesday. The stock has a market capitalization of $25.89 billion, a price-to-earnings ratio of 45.85, a PEG ratio of 1.39 and a beta of 1.47. The company has a fifty day moving average of $75.38 and a 200 day moving average of $77.80. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $93.25. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52.

DexCom (NASDAQ:DXCM) last posted its earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.03. The company had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. DexCom’s quarterly revenue was up 15.2% on a year-over-year basis. During the same period last year, the company posted $0.43 earnings per share. DexCom has set its FY 2025 guidance at EPS. As a group, sell-side analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on DXCM shares. Canaccord Genuity Group reissued a “buy” rating and issued a $106.00 price objective on shares of DexCom in a research note on Monday, September 29th. Mizuho upped their target price on shares of DexCom from $95.00 to $100.00 and gave the stock an “outperform” rating in a report on Wednesday, July 16th. Piper Sandler upped their target price on shares of DexCom from $90.00 to $100.00 and gave the stock an “overweight” rating in a report on Thursday, July 31st. Oppenheimer downgraded shares of DexCom from an “outperform” rating to a “market perform” rating in a report on Monday, September 8th. Finally, Argus initiated coverage on shares of DexCom in a report on Thursday, August 21st. They issued a “buy” rating and a $100.00 target price for the company. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, DexCom has a consensus rating of “Moderate Buy” and a consensus target price of $97.42.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.